The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress
Abstract
Hyperglycaemia is a major contributor to diabetic cardiovascular disease with hyperglycaemia-induced endothelial dysfunction recognized as the initiating cause. Coagulation pathway-regulated proteinase-activated receptors (PARs) that can regulate vascular tone in vivo cause eNOS-mediated endothelium-dependent vasodilation; but, the impact of hyperglycaemia on this vasodilatory action of PAR stimulation and the signalling pathways involved are unknown. We hypothesized that vascular sodium-glucose co-transporter 2 activity and hyperglycaemia-induced oxidative stress involving Src-kinase, EGF receptor-kinase, Rho-kinase and protein-kinase-C biochemical signalling pathways would compromise PAR2-mediated endothelium-dependent vasodilation. Using an organ culture approach, wherein murine aorta rings were maintained for 24 h at hyperglycaemic 25 mM versus euglycaemic 10 mM glucose, we observed severely blunted acetylcholine/muscarinic and PAR2-mediated endothelial eNOS/NO-dependent vasodilation. PEG-catalase, superoxide-dismutase, and NADPH-oxidase inhibition (VAS2870) and either SGLT2-inhibition (canagliflozin/dapagliflozin/empagliflozin) or antioxidant gene induction (sulforaphane), prevented the hyperglycaemia-induced impairment of PAR2-mediated vasodilation. Similarly, inhibition of Src-kinase, EGF receptor-kinase, protein kinase-C and Rho-kinase also preserved PAR2-mediated vasodilation in tissues cultured under hyperglycaemic conditions. Thus, intracellular hyperglycaemia, that can be prevented with an inhibitor of the SGLT2 cotransporter that was identified in the vascular tissue and tissue-derived cultured endothelial cells by qPCR, western blot and immunohistochemistry, leads to oxidative stress that compromises PAR2-mediated NOS-dependent vasodilation by an NAPDH oxidase/reactive-oxygen-species-triggered signalling pathway involving EGFR/Src/Rho-kinase and PKC. The data point to novel antioxidant therapeutic strategies including use of an SGLT2 inhibitor and sulforaphane to mitigate hyperglycaemia-induced endothelial dysfunction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin and other drugs used for T2DM, like the SGLT2 inhibitors, may also reduce hyperglycemia-induced elevated endothelial ROS, independent of negative effects on complex 1, such as via inhibition of NADPH oxidase or blocking the entry of glucose into the endothelium (32, 107–109, 187, 188)”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [188]
Citations
Cites
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112797 · Cited by 16,303
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Role of nrf2 in oxidative stress and toxicity
Ma, Q. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140320 · Cited by 4,903
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Thrombin signalling and protease-activated receptors
Coughlin, S. R. (2000) · Nature · doi:10.1038/35025229 · Cited by 2,495
Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947
Landmesser, U., Dikalov, S., Price, S. R., McCann, L., Fukai, T., Holland, S. M., Mitch, W. E., & Harrison, D. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200314172 · Cited by 1,660
Flagged first, then by citations
Research works printed but not linked: 1
- Triggle, 2008, The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. Timely topics in medicine, Cardiovasc. Dis., 12
Cited by
Sorted by citations
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 596
The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction
An, Y., Xu, B.-T., Wan, S., Xiu-mei, M., Long, Y., Xu, Y., & Jiang, Z. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01965-7 · Cited by 462
Oxidative Stress: Signaling Pathways, Biological Functions, and Disease
Liu, S., Liu, J., Wang, Y., Deng, F., & Deng, Z. (2025) · MedComm · doi:10.1002/mco2.70268 · Cited by 485
Bonnet, F., & Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.09.005 · Cited by 322
Yang, D., Wang, M., Zhang, C., & Wang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1359255 · Cited by 356
Mohammed, I., Hollenberg, M. D., Ding, H., & Triggle, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718942 · Cited by 278
Self-citationUthman, L., Homayr, A., Juni, R. P., Spin, E., Kerindongo, R. P., Boomsma, M., Hollmann, M. W., Preckel, B., Koolwijk, P., van Hinsbergh, V. W. M., et al. (2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000178 · Cited by 214
Juni, R. P., Kuster, D. W. D., Goebel, M., Helmes, M., Musters, R. J. P., van der Velden, J., Koolwijk, P., Paulus, W. J., & van Hinsbergh, V. W. M. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.04.003 · Cited by 208
Uthman, L., Baartscheer, A., Schumacher, C. A., Fiolet, J. W. T., Kuschma, M. C., Hollmann, M. W., Coronel, R., Weber, N. C., & Zuurbier, C. J. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01575 · Cited by 190
Daiber, A., & Chłopicki, S. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.02.026 · Cited by 171
Iannantuoni, F., M. de Marañon, A., Diaz-Morales, N., Falcon, R., Bañuls, C., Abad-Jimenez, Z., Victor, V. M., Hernandez-Mijares, A., & Rovira-Llopis, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111814 · Cited by 166
Green, J. B., Mottl, A. K., Bakris, G. L., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Nangaku, M., Rossing, P. R., Scott, C. A. B., Gay, A., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac198 · Cited by 171
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155
Endothelial response to glucose: dysfunction, metabolism, and transport
Clyne, A. M. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200611 · Cited by 168
Sayour, A. A., Korkmaz‐Icöz, S., Loganathan, S., Ruppert, M., Sayour, N. V., Oláh, A., Benke, K., Brune, M., Benkő, R., Horvath, E. M., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1881-8 · Cited by 135
Durante, W., Behnammanesh, G., & Peyton, K. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168786 · Cited by 135
Diabetes Mellitus, Mitochondrial Dysfunction and Ca2+-Dependent Permeability Transition Pore
Belosludtsev, K. N., Belosludtseva, N. V., & Dubinin, M. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186559 · Cited by 124
Luna-Marco, C., Iannantuoni, F., Hermo-Argibay, A., Devos, D., Salazar, J. D., Víctor, V. M., & Rovira-Llopis, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.01.015 · Cited by 114
Hasan, R., Lasker, S., Hasan, A., Zerin, F., Zamila, M., Chowdhury, F. I., Nayan, S. I., Rahman, M. M., Khan, F., Subhan, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71449-1 · Cited by 114
D’Onofrio, N., Sardu, C., Trotta, M. C., Scisciola, L., Turriziani, F., Ferraraccio, F., Panarese, I., Petrella, L., Fanelli, M., Modugno, P., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101337 · Cited by 108
Alshnbari, A. S., Millar, S., O’Sullivan, S. E., & IDRIS, I. R. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00885-z · Cited by 109
Ortega, R., Collado, A., Selles, F., Navarro, H. G., Sanz, M., Real, J. T., & Piqueras, L. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312659 · Cited by 102
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
Venu, V. K. P., Saifeddine, M., Mihara, K., Tsai, Y.-C., Nieves, K., Alston, L. A., Mani, S., McCoy, K. D., Hollenberg, M. D., & Hirota, S. A. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00572.2018 · Cited by 80
Juni, R. P., Al‐Shama, R., Kuster, D. W. D., van der Velden, J., Hamer, H. M., Vervloet, M. G., Eringa, E. C., Koolwijk, P., & van Hinsbergh, V. W. M. (2020) · Kidney International · doi:10.1016/j.kint.2020.12.013 · Cited by 79
Glucose transporters in cardiovascular system in health and disease
Bertrand, L., Auquier, J., Renguet, E., Angé, M., Cumps, J., Horman, S., & Beauloye, C. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02444-8 · Cited by 72
Uthman, L., Kuschma, M. C., Römer, G., Boomsma, M., Keßler, J., Hermanides, J., Hollmann, M. W., Preckel, B., Zuurbier, C. J., & Weber, N. C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07083-w · Cited by 71
Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function
Salvatore, T., Caturano, A., Galiero, R., Martino, A. D., Albanese, G., Vetrano, E., Sardu, C., Marfella, R., Rinaldi, L., & Sasso, F. C. (2021) · Biomedicines · doi:10.3390/biomedicines9101356 · Cited by 72
Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy
Phang, R. J., Ritchie, R. H., Hausenloy, D. J., Lees, J. G., & Lim, S. Y. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac049 · Cited by 67
Current and emerging drug targets in heart failure treatment
Ghionzoli, N., Gentile, F., Franco, A. D., Castiglione, V., Aimo, A., Giannoni, A., Burchielli, S., Cameli, M., Emdin, M., & Vergaro, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10137-2 · Cited by 67
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors
Ugusman, A., Kumar, J., & Aminuddin, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107832 · Cited by 59
Zhao, Z., Jiang, C., He, L., Zheng, S., Wang, Y., Gao, M., Lai, Y., Zhang, J., Li, M., Dai, W., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031269 · Cited by 51
Xu, J., Hirai, T., Koya, D., & Kitada, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010137 · Cited by 53
Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease
Triggle, C. R., Ding, H., Marei, I., Anderson, T. J., & Hollenberg, M. D. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0677 · Cited by 49
Dimitriadis, K. S., Adamopoulou, E., Pyrpyris, N., Sakalidis, A., Leontsinis, I., Manta, E., Mantzouranis, E., Beneki, E., Σουλαϊδόπουλος, Σ., Konstantinidis, D., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad053 · Cited by 50
Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis
Kang, Y.-X., Zhan, F., He, M., Liu, Z., & Song, X. (2020) · Vascular Pharmacology · doi:10.1016/j.vph.2020.106779 · Cited by 44
Exploring the Correlation and Protective Role of Diabetes Mellitus in Aortic Aneurysm Disease
Arun, D., Munir, W., Schmitt, L. V., Vyas, R., Ravindran, J. I., Bashir, M., Williams, I. M., Velayudhan, B. V., & Mohammed Idhrees, A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.769343 · Cited by 41
The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis
Stachteas, P., Karakasis, P., Patoulias, D., Clemenza, F., Fragakis, N., & Rizzo, M. (2023) · Annals of Medicine · doi:10.1080/07853890.2024.2304667 · Cited by 35
Li, X.-X., Chen, Z.-D., Sun, X.-J., Yang, Y., Jin, H. L., & Liu, N. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01217-0 · Cited by 34
Venu, V. K. P., El‐Daly, M., Saifeddine, M., Hirota, S. A., Ding, H., Triggle, C. R., & Hollenberg, M. D. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.01.005 · Cited by 30
Korkmaz‐Icöz, S., Kocer, C., Sayour, A. A., Kraft, P., Benker, M. I., Abulizi, S., Georgevici, A., Brlecic, P., Radovits, T., Loganathan, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157774 · Cited by 29
Venu, V. K. P., Saifeddine, M., Mihara, K., Faiza, M., Gorobets, E., Flewelling, A. J., Derksen, D. J., Hirota, S. A., Marei, I., Al-Majid, D., et al. (2021) · Molecular Pharmacology · doi:10.1124/molpharm.120.000148 · Cited by 30
Sarzani, R., Giulietti, F., Pentima, C. D., & Spannella, F. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.030 · Cited by 30
Campeau, M.-A., & Leask, R. L. (2022) · Scientific Reports · doi:10.1038/s41598-022-16763-6 · Cited by 28
Wang, Z., Chang, L.-L., Wu, J., Pan, H., Zhang, Q.-Y., Wang, M., Xin, X., Luo, S., Chen, J., Gu, X., et al. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7721 · Cited by 26
The Rationale and Evidence for SGLT2 Inhibitors as a Treatment for Nondiabetic Glomerular Disease
Miyata, K. N., Zhang, S., & Chan, J. S. D. (2021) · Glomerular Diseases · doi:10.1159/000513659 · Cited by 28
Penna, C. R. R., Comità, S., Tullio, F., Alloatti, G., & Pagliaro, P. (2022) · Vascular Pharmacology · doi:10.1016/j.vph.2022.106995 · Cited by 27
Awad, E. M., Ahmed, A. F., El‐Daly, M., Amin, A. H., El‐Tahawy, N. F. G., Wagdy, A., Hollenberg, M. D., & Taye, A. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113308 · Cited by 26
Synthesis and Vasodilator Activity of Some pyridazin-3(2 H )-one Based Compounds
Allam, H. A., Kamel, A., El‐Daly, M., & George, R. F. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0160 · Cited by 25
Novel Anti-inflammatory and Anti-fibrotic Agents for Diabetic Kidney Disease—From Bench to Bedside
Nicholas, S. B. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.09.010 · Cited by 25
Asada, S., Kaji, K., Nishimura, N., Koizumi, A., Matsuda, T., Tanaka, M., Yorioka, N., Sato, S., Kitagawa, K., Namisaki, T., et al. (2024) · Cells · doi:10.3390/cells13060538 · Cited by 24
Renal Dysfunction and Heart Failure with Preserved Ejection Fraction
Ananthram, M. G., & Gottlieb, S. S. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.03.005 · Cited by 28
Amelioration of Endothelial Dysfunction in Diabetes: Role of Takeda G Protein–Coupled Receptor 5
Cai, Z., Yuan, S., Zhong, Y., Deng, L., Li, J., Tan, X., & Feng, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.637051 · Cited by 23
Sanz, R. L., Inserra, F., Menéndez, S. G., Mazzei, L. J., Ferder, L., & Manucha, W. A. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01240-w · Cited by 24
Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK
Angé, M., Poortere, J. D., Ginion, A., Battault, S., Dechamps, M., Muccioli, G. G., Roumain, M., Morelle, J., Druart, S., Mathivet, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93156-1 · Cited by 21
Effect of dapagliflozin on diabetic patients with cardiovascular disease via MAPK signalling pathway
Yue, Z., Li, L., Fu, H., Yin, Y., Du, B., Wang, F., Ding, Y., Liu, Y., Zhao, R., Zhang, Z., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16786 · Cited by 18
Karakasis, P., Theofilis, P., Patoulias, D., Vlachakis, P. K., Pamporis, K., Sagris, Μ., Ktenopoulos, N., Kassimis, G., Antoniadis, A. P., & Fragakis, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104494 · Cited by 18
Hollenberg, M. D., & Epstein, M. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.12.001 · Cited by 16
Shi, Z., Gao, F., Liu, W., & He, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.869272 · Cited by 18
Avdonin, P. V., Rybakova, E. Y., Авдонин, П. П., Авдонин, П. П., Авдонин, П. П., Tsitrina, A. A., & Goncharov, N. V. (2019) · Cells · doi:10.3390/cells8020196 · Cited by 18
Elbaz, E. M., Darwish, A., Gad, A. M., Rahman, A. A. S. A., & Safwat, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175993 · Cited by 18
Ahmed, Y. M., Messiha, B. A. S., El‐Daly, M., & Abo‐Saif, A. A. (2019) · Pharmacological Reports · doi:10.1016/j.pharep.2019.06.004 · Cited by 17
Xu, M., Li, Z., Yang, L., Zhai, W., Wei, N., Zhang, Q., Chao, B., Huang, S., & Cui, H. (2020) · BioMed Research International · doi:10.1155/2020/5848497 · Cited by 17
Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms
Xiao, L., Nie, X., Cheng, Y., & Wang, N. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07216-9 · Cited by 16
Hoehlschen, J., Hofreither, D., Tomin, T., & Birner‐Gruenberger, R. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01822-7 · Cited by 13
Barraclough, J., Patel, S., Yu, J., Neal, B. C., & Arnott, C. G. (2021) · Cells · doi:10.3390/cells10102699 · Cited by 13
Li, B., Li, Y., Li, S., Li, H., Liu, L., & Xu, Y. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s343864 · Cited by 12
Miceli, G., Basso, M. G., Pennacchio, A. R., Cocciola, E., Pintus, C., Cuffaro, M., Profita, M., Rizzo, G., Sferruzza, M., & Tuttolomondo, A. (2024) · Medicina · doi:10.3390/medicina60111796 · Cited by 13
Paracha, T. U., Pobsuk, N., Salaloy, N., Suphakun, P., Pekthong, D., Hannongbua, S., Choowongkomon, K., Khorana, N., Temkitthawon, P., Ingkaninan, K., et al. (2019) · Molecules · doi:10.3390/molecules24020281 · Cited by 12
Zheng, R., Song, W., Lu, J. L., Yuan, M., Sun, X., & Lu, C. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02600-3 · Cited by 11
Stuart, D., Peterson, C. S., Hu, C., Revelo, M. P., Huang, Y., Kohan, D. E., & Ramkumar, N. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2022-0082 · Cited by 10
Campeau, M., & Leask, R. (2023) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-023-02607-1 · Cited by 9
Microvascular dysfunction: Determinants and treatment, with a focus on hyperglycemia
Houben, A. J. H. M., & Stehouwer, C. D. A. (2020) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2020.100073 · Cited by 10
Zhang, J., Ye, X.-R., Liu, X., Zhang, H.-L., & Qiao, Q. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i1.101491 · Cited by 9
SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms
Zhang, Y., He, Y., Liu, S., Deng, L., Zuo, Y., Huang, K., Liao, B., Li, G., & Feng, J. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00602-8 · Cited by 10
Impact of currently used anti-diabetic drugs on myoendothelial communication
Ding, H., Ye, K., & Triggle, C. R. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.11.002 · Cited by 9
Liu, X., Zhang, T., Fu, R., Liu, D., Zhang, J., Hu, Q., Song, G., & Ren, L. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02723-7 · Cited by 7
Campos, E. G., Páez, F. G., Becerra, C. G. R., Balleza-Alejandri, L. R., Suárez-Rico, D. O., Cardona-Muñóz, E. G., González, S. P., Ramos-Zavala, M. G., Beltrán-Ramírez, A., García-Galindo, J. J., et al. (2025) · Life · doi:10.3390/life15050802 · Cited by 7
Hua, T., Chu, Y., Wang, M., Zhang, Y., Shi, W., Huang, Q., Zhang, L., & Yang, M. (2023) · Intensive Care Medicine Experimental · doi:10.1186/s40635-023-00562-y · Cited by 7
Chen, G., Wang, H., Zhang, W., & Zhou, J. (2021) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2021.0086 · Cited by 6
Effects of dietary palmitoleic acid on vascular function in aorta of diabetic mice
Takenouchi, Y., Seki, Y., Shiba, S., Ohtake, K., Nobe, K., & Kasono, K. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01018-2 · Cited by 6
SGLT2 Inhibitors After Myocardial Infarction: Evidence, Mechanisms and Gaps in Knowledge
Buonpane, A., Ciardetti, M., Trimarchi, G., Scalone, G., Coceani, M. A., Pastormerlo, L. E., Marchi, F., Paradossi, U., Berti, S., Passino, C., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062260 · Cited by 5
Balleza-Alejandri, L. R., Páez, F. G., Campos, E. G., Becerra, C. G. R., Muñoz, E., González, S. P., Ramos-Zavala, M. G., Reynoso-Roa, A. S., Suárez-Rico, D. O., Beltrán-Ramírez, A., et al. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11060182 · Cited by 5
Aziz, M. W., Mohamed, K. O., Farag, D. B., Khalifa, A. K., & Mahmoud, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-79697-1 · Cited by 5
Seo, M. S., An, J. R., Kang, M., Heo, R., Park, H., Han, E., Han, J., Chun, W., & Park, W. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120101 · Cited by 5
New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
Li, J., Zhou, L., & Gong, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903902 · Cited by 6
Wang, J., Li, D., Ju, W., & Wang, H. (2022) · Journal of Vascular Diseases · doi:10.3390/jvd1010007 · Cited by 5
Anastasiou, G., Hatziagelaki, E. E., & Liberopoulos, E. N. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001011 · Cited by 6
Čináková, A., Křenek, P., Klimas, J., & Kráľová, E. (2023) · Pharmacology · doi:10.1159/000533592 · Cited by 4
Panigrahi, S., Mayne, E. S., Louw, S. J., Funderburg, N., Chakraborty, A., Jacobson, J. M., Carpenter, S. M., Lederman, M. M., Freeman, M. L., & Sieg, S. F. (2024) · iScience · doi:10.1016/j.isci.2024.110909 · Cited by 4
Awad, E. M., Ahmed, A. F., El‐Daly, M., El‐Tahawy, N. F. G., Kasem, A. W., & Taye, A. (2021) · Journal of advanced Biomedical and Pharmaceutical Sciences · doi:10.21608/jabps.2021.95071.1139 · Cited by 4
Li, G., Mu, J., Liu, X., He, J., Ji, F., Wang, W., & Liu, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01916-0 · Cited by 3
Keskin, B., Hakgör, A., Khidolda, Y., Dursun, A., Akhundova, A., Savur, Ü., Olgun, F. E., Onder, O., Gül, Y. G., Çakal, B., et al. (2026) · Medicina · doi:10.3390/medicina62030535 · Cited by 3
Nieczyporuk, M., Tyrna, P., Cader, T., Sikora, A., & Staneta, S. (2024) · Journal of Endocrinology and Metabolism · doi:10.14740/jem942 · Cited by 3
Sodium-glucose co-transporter inhibitors for APOL1 kidney disease: A call for studies
Afşar, B., Afşar, R. E., Çalışkan, Y., & Lentine, K. L. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04443-z · Cited by 3
Hsieh, M., Chen, D., Lee, C.-H., Liao, Y.-C., Lin, M., & Pang, J. S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04179-8 · Cited by 2
Ahmed, A., Abdel-Rahman, D., & Hantash, E. M. (2023) · Biotechnic & Histochemistry · doi:10.1080/10520295.2023.2262390 · Cited by 2
Polynorepinephrine nanoparticles activate vascular smooth muscle alpha-1 adrenergic receptors
Kollath, V. O., Venu, V. K. P., Saifeddine, M., Mihara, K., Hirota, S. A., Hollenberg, M. D., & Karan, K. (2024) · Nanoscale Advances · doi:10.1039/d4na00481g · Cited by 2
Empagliflozin and Protecting Microvascular Support of Heart Mechanics
Mantsounga, C., & Morrison, A. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.08.003 · Cited by 2
Chung, C., Lu, H., Chung, M., Wu, L., Huo, C., Kuo, L., Liu, C., & Chuu, C. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040260 · Cited by 1
Metadata
- Authors
- El-Daly, M., Pulakazhi Venu, V. K., Saifeddine, M., Mihara, K., Kang, S., Fedak, P. W. M., Alston, L. A., Hirota, S. A., Ding, H., Triggle, C. R., & Hollenberg, M. D.
- Affiliations
- University of Calgary (CA)
- Weill Cornell Medical College in Qatar (QA)
- Corresponding author
- Hollenberg, Morley D.
- ORCID
- Venue
- Vascular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 109
- Pages
- 56-71
- ISSN
- 1537-1891 (ISSN-L)
- OpenAlex
- W2808400246
- Cited by
- 117
- References
- 78
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 11 · 2023: 14 · 2022: 16 · 2021: 26 · 2020: 15 · 2019: 14 · 2018: 3
- FWCI
- 9.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Vascular Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Qatar Foundation National Priorities Research Program (NPRP: 08165-3-054), 4-910-3-244)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Keywords
- hyperglycemia, protease-activated receptor 2, endothelium-dependent vasodilation, endothelial dysfunction, SGLT2, SGLT2 inhibitors, oxidative stress, NADPH oxidase, reactive oxygen species, Src kinase, EGF receptor, Rho kinase, protein kinase C, sulforaphane, antioxidant therapy, diabetic cardiovascular disease, aortic endothelium
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Antioxidants, Aorta, Dose-Response Relationship, Drug, Endothelium, Vascular, Hyperglycemia, Hypoglycemic Agents, Male, Mice, Inbred C57BL, Mitochondria, Nitric Oxide, Organ Culture Techniques, Protein Kinase C, Vasodilation, Signal Transduction, Oxidative Stress, src-Family Kinases, Endothelial Cells, Receptor, PAR-2, Sodium-Glucose Transporter 2, Nitric Oxide Synthase Type II, rho-Associated Kinases, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
